Bone-Rad Therapeutics, Inc. is a Delaware corporation whose objective is to develop and market brachytherapy bone cement as an innovative, improved, and cost-effective treatment paradigm in the management of tumors in bone.
Bone-Rad Therapeutics was formed after the company co-founders entered and won the 2007 Stradling Yocca Carlson and Rauth Business Plan Competition at the University of California, Irvine (UCI). Members of the team were also awarded a three-year $760,000 research grant from the Department of Defense Breast Cancer Research Program in 2007, which funded nonclinical laboratory studies completed at UCI. Bone-Rad Therapeutics entered into an exclusive license agreement for the technology with the University of California in 2010.
Bone-Rad’s first product, Spine-Rad™ Cement, will target tumors in the spine, the most common site for bone metastases. Spine-Rad™ Cement is a proprietary technology that incorporates phosphorus-32 (P-32), a common medical radionuclide, within standard polymethylmethacrylate (PMMA) bone cement. Spine-Rad™ Cement is injected into the vertebrae using conventional vertebroplasty and kyphoplasty procedures.
Bone-Rad team members pose with coaches after winning the 2007 Stradling Yocca Carlson and Rauth Business Plan Competition at the University of California, Irvine.
Spine-Rad™ Cement is designed to provide local, targeted irradiation to assist in the prevention of tumor progression in the surrounding bone, while simultaneously restoring bone strength. When used in the spine, Spine-Rad™ Cement combines and simplifies the current two-step process for treatment of spinal tumors—vertebroplasty or kyphoplasty followed by external beam radiation therapy (EBRT). The product concept is analogous to the internally-targeted treatment of breast and prostate cancer tumors using brachytherapy techniques.